← Back to AKTSPortrait, one to two pages. Turn on “background graphics” in the print dialog to keep the table rules.

SPZCOAktis Oncology, Inc. · AKTSData at close 2026-07-29

Health Care · Pharmaceutical Preparations · Nasdaq · CIK 2035832 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote

Last $22.39Day −2.53%1Y +22389900.0%Off 52W high −34.5%Vol (1Y) 2017834.7%

Price2023-07-31 → 2026-07-29

AKTS close: $2.4 on 2023-07-31 to $22.4 on 2026-07-29.

Daily closing price, split-adjusted to the current basis; 2y shown of 2,447 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.

At a glance

Days to cover6.3d

Top-10 13F concentration72.5%

Next report (est.)2026-08-03

Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.

Key fundamentals

No standardized fundamentals available.

Trailing returns

YTD+1492566.7%

1Y+22389900.0%

3Y+836.8%

5Y+124.8%

10Y+497.1%

Since incept. (ann.)+25.4%

Total return through 2026-07-29 · series begins 2015-11-20. Only the windows this history actually covers are shown.

Risk

Ann. volatility (1Y)2017834.7%

Ann. volatility (3Y)1045553.1%

Sharpe (1Y)1.35

Sharpe (3Y)0.70

Max drawdown (1Y)−32.2%

Max drawdown (3Y)−100.0%

Beta (3Y vs SPY)14980.17

Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.

Top institutional holders13F 2026-Q1

Manager	Shares	Value	% sh out	QoQ
MPM BIOIMPACT LLC	4.8M	$87M	—	new
EcoR1 Capital, LLC	4.8M	$86M	—	new
Blue Owl Capital Holdings LP	3.2M	$57M	—	new
WELLINGTON MANAGEMENT GROUP LLP	2.3M	$41M	—	new
T. Rowe Price Investment Management, Inc.	2.1M	$38M	—	new
BlackRock, Inc.	2.1M	$38M	—	new
RTW INVESTMENTS, LP	1.6M	$28M	—	new
PRICE T ROWE ASSOCIATES INC /MD/	1.6M	$28M	—	new

Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.

Latest reported quarterslast report 2026-05-11

No reported quarters on file for AKTS.

Basis & disclosures

End-of-day only. Every price on this sheet is a stored CLOSE — the last one is 2026-07-29. Nothing here is live, intraday or delayed-real-time, and the sheet does not update after it is printed.
Nothing is imputed. A figure that is not in the underlying filing or feed renders as “—”. We never fill a gap with an estimate, a peer median or a carried-forward value.
Mixed as-of dates by design. Prices are at the last close; fundamentals are at the latest reported fiscal period; 13F ownership is at the latest filed quarter (45+ days in arrears); short interest is the latest FINRA settlement. Each block states its own basis above.
Not investment advice. Model fair values, reverse-DCF grades and confidence labels are the output of published, disclosed methods on public filings — they are analysis, not a recommendation, a price target or a solicitation.
Fundamentals and ownership derive from SEC EDGAR (and equivalent foreign registers); prices from a licensed end-of-day vendor, shown under a neutral source label. Full methodology at spzco.com/methodology.